A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects

Phase 1 Completed 12 enrolled Intra-Cellular Therapies, Inc. National Institute on Drug Abuse (NIDA) · collab

RandomizedSequentialOpen-labelBasic science

Summary

This is an open-label, single-dose study of up to 4 dose levels of ITI-333 in healthy male and female subjects. Each cohort will enroll 6 subjects. Subjects will have a baseline PET/CT scan and a postdose PET/CT scan using \[14C\]-MDL100907 to characterize 5-HT2A receptor occupancy

Timeline

Start: 2022-07-26
Primary completion: 2023-05-03
Completion: 2023-05-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ITI-333	Unknown	2.25 mg	Oral

Indications

No indication recorded.